Taylor Harris Named to Establishment Labs’ Board of Directors

Establishment Labs Holdings Inc. has appointed Taylor Harris to its Board of Directors.

Harris has more than 25 years of experience in corporate finance, executive leadership, and board governance across healthcare, medical technology, and life sciences companies. He currently serves on the Board of Directors of Procept BioRobotics and previously served as a director of Omada Health and Endologix. Most recently, he was CEO of Cutera Inc.

“Taylor is a highly regarded and accomplished healthcare executive whose experience will help Establishment Labs through its next phase of growth,” Establishment Labs Board Chairman Nick Lewin said. “Importantly, he brings deep expertise in the medical aesthetics industry and has helped lead and create substantial value at multiple healthcare companies. His perspective on sustained growth through innovation and focus on shareholder value creation will be a tremendous asset to Establishment Labs as it becomes a leader in the global aesthetics market.”

Before Cutera, Harris was chief financial officer (CFO) at MyoKardia, where he helped guide the company through its $13.1 billion acquisition by Bristol Myers Squibb. Earlier in his career, he worked as CFO at Zeltiq Aesthetics through its acquisition by Allergan and as CFO at Thoratec Corporation through its acquisition by St. Jude Medical. He also spent more than a decade at JPMorgan Chase & Co. in healthcare equity research and investment banking roles.

“I am honored to join the Board of Establishment Labs at such an exciting time,” Harris stated. “The company has built a reputation for innovation, quality, and a strong commitment to improving outcomes for women around the world, and is in a position to become one of the most important companies in aesthetics and healthcare. I look forward to being part of the journey.”

Establishment Labs Holdings Inc. is a global medical device company dedicated to improving women’s health and wellness in breast aesthetics and reconstruction through science, engineering, and technology. The company offers solutions for breast health, breast aesthetics, and breast reconstruction in more than 100 countries. With 5 million Motiva devices delivered to plastic and reconstructive surgeons since 2010, the company’s products have created a new standard for safety and patient satisfaction, executives claim. The company’s minimally invasive platform consists of Mia Femtech, a unique minimally invasive experience for breast harmonization, and Preservé, a breast tissue preserving and minimally invasive technology for primary breast augmentation and primary mastopexy augmentation. GEM is a next-generation minimally invasive system for gluteal ergonomic modeling currently undergoing an IRB-approved pivotal study. The Motiva Flora tissue expander is used to improve outcomes in breast reconstruction following breast cancer and reportedly is the world’s only regulatory-approved expander with an integrated port using radio-frequency technology that is MRI conditional. Zensor is an RFID technology platform used to safely identify implantable devices from outside the body, and includes the company’s first biosensor Zenº, currently part of an IRB-approved pivotal study to measure core breast temperature. These solutions are supported by more than 200 patent applications in 20 separate patent families worldwide and over 100 scientific and clinical studies and publications in peer-reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica, compliant with all applicable regulatory standards under ISO13485:2024 and U.S. Food and Drug Administration 21 CFR 820.